Using Stellate Ganglion Block to Treat Heart Failure
Stellate Ganglion Block as Novel Treatment for Heart Failure Patients
PHASE2; PHASE3 · Assiut University · NCT06244056
This study is testing if a special nerve block treatment can help people with severe heart failure feel better while they are on their usual medications.
Quick facts
| Phase | PHASE2; PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 108 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Assiut University (other) |
| Locations | 2 sites (Assiut and 1 other locations) |
| Trial ID | NCT06244056 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of Stellate Ganglion Block as a treatment for patients suffering from heart failure. The study aims to enroll individuals aged 18 to 70 with NYHA Class III-IV heart failure and a reduced ejection fraction. Participants will receive the Stellate Ganglion Block intervention while being on optimal medical therapy for heart failure. The trial is designed to assess the potential benefits of this novel approach in improving heart failure symptoms and overall patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 70 with NYHA Class III-IV heart failure and a reduced ejection fraction.
Not a fit: Patients with active malignancy, acute heart failure, or severe non-cardiac diseases are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life and heart function for patients with heart failure.
How similar studies have performed: While the approach of using Stellate Ganglion Block is novel for heart failure, similar interventions have shown promise in other conditions, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 : 70 years old. * NYHA Class III-IV Heart Failure. * Heart failure with a reduced ejection fraction (HFrEF) LVEF ≤ 40% calculated using 2D echocardiography and Biplane Simpson's . * Optimal tolerated Medical Therapy for Heart Failure. Exclusion Criteria: * Active Malignancy. * Acute heart failure including pulmonary edema or cardiogenic shock. * Severe, life-threatening non-cardiac disease. * Pregnancy. * Localized infection. * Coagulopathy or anticoagulated patients. * Refused this procedure.
Where this trial is running
Assiut and 1 other locations
- Assiut University — Assiut, Egypt (NOT_YET_RECRUITING)
- Assiut university — Assiut, Egypt (RECRUITING)
Study contacts
- Study coordinator: Mina Fam, Resident
- Email: minassfam@yahoo.com
- Phone: 01122035368
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Stellate Ganglion Block